JTC’s Post

Check out our latest corporate presentation to learn more about Kaida and how we are working to #EndOvarianCancer. https://bit.ly/3SagUwP #OvarianCancer #OvarianCancerResearch #NoWomanLeftBehind

🎙️ In the latest Uromigos episode, Brian Rini, MD, FASCO, and Tom Powles, MBBS, MRCP, MD, sat down with Tanya Dorff, MD, to discuss her work investigating {hashtag|\#|acapatamab}, a {hashtag|\#|CD3} and {hashtag|\#|PSMA} bispecific t-cell engaging antibody studied in advanced {hashtag|\#|ProstateCancer}. 👂 Listen Here:

At the ESMO - European Society for Medical Oncology Congress 2024, the results of the KEYNOTE-811 trial were presented. The data positions pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment option for HER2-positive metastatic G/GEJ adenocarcinoma, particularly in patients with higher PD-L1 expression. 🔗See more from the ESMO 2024 congress: https://lnkd.in/dP9ADU5Y #ESMO24 #Esophaguscancer

🎙️ In episode 309 of the the Uromigos, Brian Rini, MD, FASCO, and Tom Powles, MBBS, MRCP, MD, talk with Matt Galsky, MD, about the #OS signal data from #CheckMate274, which analyzed the use of #adjuvant #nivolumab in patients with #MIBC. 👉 Listen Here:

Hear more about the primary results of the PALOMA-3 trial assessing the OS & non-inferiority of subcutaneous amivantamab vs IV amivantamab, in combo w/ lazertinib, in EGFR-mutated, advanced non-small cell #LungCancer. #lcsm https://lnkd.in/grQbB4WU

👀 #ICYMI: Laurence Albiges, MD, sat down with the Uromigos (Brian Rini, MD, FASCO, Tom Powles, MBBS, MRCP, MD) to discuss the KIM-1 circulating #biomarker, which may have predictive and prognostic capabilities for #KidneyCancer. 👂 Listen Now:

Hear more about the primary results of the PALOMA-3 trial assessing the OS & non-inferiority of subcutaneous amivantamab vs IV amivantamab, in combo w/ lazertinib, in EGFR-mutated, advanced non-small cell #LungCancer. #lcsm https://lnkd.in/eiwTPcXR

Mesa Mayor Giles said it best: "This investment brings dozens of well-paying jobs to our city, boosting our local economy and enhancing our reputation as a hub for innovation." This new Mesa facility, along with another in Pennsylvania, will bring cutting-edge research, development, and manufacturing capabilities under one roof, giving Nucleus and its partners a huge time and scale advantage. For our city, this means: - Economic Growth: The facility is expected to create about 50 high-paying jobs, contributing to local economic development and reinforcing Mesa’s growing reputation as a hub for innovation. - Improved Patient Access: Radiopharmaceuticals often have short half-lives, meaning they need to be produced near where they’re used. Having this facility in Mesa ensures faster and more reliable access to life-saving therapies for patients across the Southwest. - National Impact: By addressing supply chain constraints and accelerating drug development timelines, Nucleus’ expansion will not only benefit Mesa but also improve patient outcomes across the country. Faster clinical trials and reduced time-to-market for new therapies could be game-changing for healthcare. Awesome to see City of Mesa contributing to such groundbreaking work that will impact the future of healthcare nationwide. City of Mesa Office of Economic Development #MesaAZ #Arizona #EconomicDevelopment #EconDev #Innovation

Yesterday at #ASCO24, Shasqi’s Founder & CEO, José M. Mejía Oneto presented data from our Phase 2a study in patients with soft tissue sarcoma. This trial represents the first successful dose escalation of doxorubicin beyond 4x in a clinical trial: using our CAPAC technology to activate chemotherapy at the tumor, we were able to dose 12x the standard dose of doxorubicin per cycle without any DLTs, and with mild and manageable myelosuppression. Thanks to our PIs: Nam Bui, Vineet Kwatra, Christopher W. Ryan, MD, Erlinda Maria Gordon MD and Sant Chawla and to the patients and their families for participating in this study. Read the full poster here👇 https://bit.ly/3VpEuHR

This clip from Sona Nanotech's latest webinar highlights the key advancements in targeted hypothermia therapy. Learn about their strategic partnerships, IP protection, and insights from Sona team. Watch the full webinar extract here: https://lnkd.in/ekuheA-P #oncologyresearch #cancerresearch #colorectalcancer #bowelcancer #cancerresearchuk #colorectalcancercanada #ColonCancer #medicaltechnology